JP2022544485A5 - - Google Patents
Info
- Publication number
- JP2022544485A5 JP2022544485A5 JP2022508487A JP2022508487A JP2022544485A5 JP 2022544485 A5 JP2022544485 A5 JP 2022544485A5 JP 2022508487 A JP2022508487 A JP 2022508487A JP 2022508487 A JP2022508487 A JP 2022508487A JP 2022544485 A5 JP2022544485 A5 JP 2022544485A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064712A JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885732P | 2019-08-12 | 2019-08-12 | |
| US62/885,732 | 2019-08-12 | ||
| US201962935526P | 2019-11-14 | 2019-11-14 | |
| US62/935,526 | 2019-11-14 | ||
| PCT/US2020/045584 WO2021030248A1 (en) | 2019-08-12 | 2020-08-10 | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064712A Division JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022544485A JP2022544485A (ja) | 2022-10-19 |
| JPWO2021030248A5 JPWO2021030248A5 (https=) | 2023-08-21 |
| JP2022544485A5 true JP2022544485A5 (https=) | 2023-08-21 |
| JP7667132B2 JP7667132B2 (ja) | 2025-04-22 |
Family
ID=72193647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508487A Active JP7667132B2 (ja) | 2019-08-12 | 2020-08-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
| JP2025064712A Pending JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064712A Pending JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11576919B2 (https=) |
| EP (1) | EP4013419A1 (https=) |
| JP (2) | JP7667132B2 (https=) |
| CN (1) | CN114206345A (https=) |
| TW (1) | TW202120096A (https=) |
| WO (1) | WO2021030248A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113194941A (zh) | 2018-12-19 | 2021-07-30 | 基因泰克公司 | 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌 |
| WO2021030248A1 (en) | 2019-08-12 | 2021-02-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant |
| CA3240454A1 (en) * | 2021-12-10 | 2023-06-15 | Lacey Morgan LITCHFIELD | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito |
| WO2024083716A1 (en) * | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
| IL324442A (en) * | 2023-05-05 | 2026-01-01 | Astrazeneca Ab | Combination of captopril, a cdk4/6 inhibitor, and fulvestrant for use in the treatment of breast cancer |
| CN121586576A (zh) * | 2023-06-14 | 2026-02-27 | 南京正大天晴制药有限公司 | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102021157B1 (ko) * | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| HRP20200992T1 (hr) * | 2012-05-17 | 2020-10-16 | Genentech, Inc. | Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci |
| JP2017507964A (ja) * | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
| WO2017161253A1 (en) * | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| TWI777658B (zh) * | 2016-08-10 | 2022-09-11 | 瑞士商赫孚孟拉羅股份公司 | 包含Akt蛋白質激酶抑制劑之醫藥組合物 |
| CN109982701B (zh) | 2017-06-21 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 |
| WO2021030248A1 (en) * | 2019-08-12 | 2021-02-18 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant |
| JP2022547735A (ja) * | 2019-09-16 | 2022-11-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 乳房がんの分子特徴付けに基づく処置の方法 |
-
2020
- 2020-08-10 WO PCT/US2020/045584 patent/WO2021030248A1/en not_active Ceased
- 2020-08-10 CN CN202080056620.0A patent/CN114206345A/zh active Pending
- 2020-08-10 TW TW109127081A patent/TW202120096A/zh unknown
- 2020-08-10 JP JP2022508487A patent/JP7667132B2/ja active Active
- 2020-08-10 EP EP20761063.5A patent/EP4013419A1/en active Pending
- 2020-08-10 US US16/989,528 patent/US11576919B2/en active Active
-
2023
- 2023-01-25 US US18/101,377 patent/US12083129B2/en active Active
-
2024
- 2024-08-28 US US18/817,828 patent/US20250161322A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064712A patent/JP2025121905A/ja active Pending